Related Experiment Video

Updated: Oct 17, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Risk factors of sudden cardiac death in hypertrophic cardiomyopathy

Ying Hong1,2,3, Wilber W Su4, Xiaoping Li2,3

  • 1Department of Cardiology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Current Opinion in Cardiology
|October 12, 2021
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a major cause of sudden cardiac death (SCD) in young individuals. Identifying risk factors like family history and syncope is crucial for better risk stratification in HCM patients.

Area of Science:

  • Cardiology
  • Genetics
  • Sudden Cardiac Death

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death (SCD) in young individuals and athletes.
  • Identifying individuals at high risk for SCD is critical for timely intervention.
  • Current risk stratification methods for HCM-related SCD require continuous improvement.

Purpose of the Study:

  • To review and synthesize recent findings on risk factors for SCD in patients with HCM.
  • To discuss established and emerging risk markers for HCM-related SCD.
  • To highlight the ongoing challenges in predicting SCD in HCM patients.

Main Methods:

  • Systematic review of recent literature.
  • Analysis of established risk factors for SCD in HCM.
  • Exploration of novel risk markers and improved risk stratification tools.

Main Results:

  • Established risk factors include a family history of SCD and unexplained syncope.
  • New risk markers are continually emerging from ongoing research.
  • Despite advancements, predicting SCD in HCM patients remains challenging, with an annual incidence of approximately 1%.

Conclusions:

  • Accurate risk stratification for SCD in HCM patients is complex and remains a clinical challenge.
  • Further research into individual risk factors is necessary for improved prediction.
  • Identifying independent risk factors is key to enhancing risk stratification strategies.
Abstract

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
124
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
151
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
103
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77